Ishida Seiichi
Division of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Biological Safety Research Center, National Institute of Health Sciences, Kawasaki, Japan.
Front Toxicol. 2021 Apr 29;3:657765. doi: 10.3389/ftox.2021.657765. eCollection 2021.
Microphysiological systems (MPS) have been actively developed as a new technology for toxicity testing platforms in recent years. MPS are culture techniques for the reconstruction of the specific functions of human organs or tissues in a limited space to create miniaturized human test systems. MPS have great promise as next-generation toxicity assessment systems. Here, I will review the current status of MPS and discuss the requirements that must be met in order for MPS to be implemented in the field of drug discovery, presenting the example of an cell assay system for drug-induced liver injury, which is the research subject in our laboratory. Projects aimed at the development of MPS were implemented early in Europe and the United States, and the AMED-MPS project was launched in Japan in 2017. The AMED-MPS project involves industry, government, and academia. Researchers in the field of drug discovery in the pharmaceutical industry also participate in the project. Based on the discussions made in the project, I will introduce the requirements that need to be met by liver-MPS as toxicity test platforms.
近年来，微生理系统（MPS）作为一种用于毒性测试平台的新技术得到了积极发展。MPS是一种培养技术，用于在有限空间内重建人体器官或组织的特定功能，以创建小型化的人体测试系统。MPS作为下一代毒性评估系统具有巨大潜力。在此，我将回顾MPS的现状，并讨论MPS在药物发现领域得以应用必须满足的要求，以我们实验室的研究课题——药物性肝损伤细胞检测系统为例进行说明。旨在开发MPS的项目在欧洲和美国早期就已实施，2017年日本启动了AMED-MPS项目。AMED-MPS项目涉及产业界、政府和学术界。制药行业药物发现领域的研究人员也参与了该项目。基于项目中的讨论，我将介绍肝脏MPS作为毒性测试平台需要满足的要求。
